We recently reported on 68Ga- and 89Zr-labelled mono-, di- and trimeric minigastrin (MG) analogues utilizing fusarinine C (FSC) as bifunctional chelator (BFC) for targeting cholecystokinin-2 receptor (CCK2R) expression which is involved in various malignancies as medullary thyroid carcinoma (MTC), small cell lung cancer (SCLC) and stromal ovarian cancer[14]. This evidence concerns the gene CCKBR and medullary thyroid gland carcinoma.